#News: We’re excited to announce our upcoming oncology and hematology data that has been recently accepted at @ASCO Annual Meeting and @eha_hematology 2025 Congress. #ASCO25 #EHA2025.

Novartis had a strong Q1 2025 with double-digit sales growth, robust margin expansion and significant pipeline progress, including 3 new product approvals. We upgraded our full-year guidance and remain focused on advancing our pipeline and achieving our growth outlook.

On Tuesday, April 29 Novartis will announce its Q1 2025 earnings. Register to listen here: #NovartisNews $NVS $NOVN #NVSQ12025

Marc’s journey from unexpected heart attacks to a life-changing diagnosis of “a genetic condition” has transformed his family's life. Learn more: #Novartis #NovartisLive #CVD

This FDA approval is a testament to our commitment to advancing prostate cancer care through research and innovation. Every achievement is driven by our dedication to transforming lives and giving patients what matters most – more options. #ReimaginingMedicine.

Heart disease is a major health challenge in Japan. We explore Dr. Muto’s vision of a healthcare landscape that seamlessly unites human connection and digital precision to enhance patient care. Learn more: #Novartis #NovartisLive #CVD

Cardiovascular diseases claim nearly 18 million lives annually. At Novartis, we're committed to changing this. Through innovative therapies and partnerships, we're tackling this public health challenge head-on. Learn more: #Novartis #NovartisLive #CVD

Glad we got your attention! Now let’s get serious—Early detection can be a game changer in the fight against breast cancer. Know your risk, get screened. Visit @SusanGKomen @LivingBeyondBC @touchbbca @Breastcancerorg @sistersnetwork @knowyourlemons

#Investors: In our first full-year as a pure-play innovative medicines company, Novartis delivered stand-out FY 2024 performance delivering strong sales growth with margin expansion and achieving several key innovation milestones. #NVSQ424.

#NVSQ424 Novartis social media posts on Q4 and Full-Year 2024 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: $NVS.

On Friday, January 31 Novartis will announce its Q4 and Full-Year 2024 results. Register to listen here: #NovartisNews $NVS $NOVN #NVSQ424.

Innovation only matters when it reaches those who need it. Today, we are honored that Novartis has been ranked first in the 2024 Access to Medicine Index. This recognition reinforces our commitment to improving access to breakthrough medicines for people around the world,

As a part of our 20+-year commitment to innovation and support in CML, we continue to work alongside the clinical and patient communities. #ReimaginingMedicine.

For more than 2 decades, we've been working diligently to develop medicine for people living with chronic myeloid leukemia (#CML). This FDA approval reflects our ongoing commitment to that community. #ReimaginingMedicine.

Novartis delivered strong operational performance and achieved key pipeline milestones in Q3, supporting further upgrade to FY24 guidance. Performance reflects continued strong operational performance, with all key growth drivers contributing to momentum. $NVS $NOVN #NVSQ324.

#NVSQ324 Novartis social media posts on Q3 2024 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information $NVS $NOVN.

Novartis will issue Q3 2024 results on Tuesday, October 29. We invite #investors to our #earnings webcast to hear updates on our growth and performance. $NVS $NOVN #NVSQ324.

RT @NovartisNews: Today’s FDA approval of a new treatment to reduce recurrence risk for a broad population of people diagnosed with HR+/HER….

We commit to the #RadioligandTherapy (RLT) demands of tomorrow by planning today. #ReimaginingMedicine.

It is through research like the City Heartbeat Index and the greater understanding it brings that, together with our partners, we are better placed to support the development of targeted public health interventions based on individual needs of each city.